Related Experiment Video

Updated: Sep 20, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Growth factors and chemotherapeutic modulation of breast cancer cells

Kadriye Ciftci1, Jiangfeng Su, Peter B Trovitch

  • 1Temple University, School of Pharmacy, Department of Pharmaceutical Sciences, 3307 N. Broad Street, Philadelphia, PA 19140, USA. kadriye.ciftci@temple.edu

The Journal of Pharmacy and Pharmacology
|September 6, 2003
PubMed

Insights

Osteoblast-derived growth factors like IGF-1 and TGF-beta1 can alter breast cancer cell responses to doxorubicin chemotherapy. These factors may offer new strategies for modulating chemotherapy effectiveness in breast cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Breast cancer metastasis to bone involves various molecules, including growth factors.
  • Osteoblast-derived growth factors, such as insulin-like growth factor-1 (IGF-1) and transforming growth factor beta-1 (TGF-beta1), play a role in cancer progression.
  • Estrogen receptor-positive (ER+) and negative (ER-) breast cancer cell lines exhibit differential responses to chemotherapy.

Purpose of the Study:

  • To investigate the effects of IGF-1 and TGF-beta1 on doxorubicin-induced apoptosis and growth arrest in ER+ (MCF-7) and ER- (MDA-MB-435) breast cancer cell lines.
  • To compare the cytotoxicity of doxorubicin in normal breast epithelial cells (MCF-10A) versus breast cancer cell lines.
  • To explore the potential of osteoblast-derived growth factors in modulating breast cancer chemotherapy response.

Main Methods:

  • Exposure of MCF-10A, MCF-7, and MDA-MB-435 cell lines to varying doses and durations of doxorubicin.
  • Assessment of doxorubicin-induced apoptosis using flow cytometry, DNA fragmentation, and TUNEL assays.
  • Evaluation of the impact of exogenous IGF-1 and TGF-beta1 on doxorubicin cytotoxicity and cell cycle progression.

Main Results:

  • Doxorubicin exhibited higher cytotoxicity in MDA-MB-435 and MCF-7 cancer cells compared to MCF-10A normal cells.
  • Doxorubicin induced G2/M phase blockade and apoptosis in MDA-MB-435 cells.
  • IGF-1 partially neutralized doxorubicin cytotoxicity in both cancer cell lines, while TGF-beta1 showed differential effects on cell cycle phases in MCF-7 and MDA-MB-435 cells.

Conclusions:

  • Osteoblast-derived growth factors can significantly influence the chemotherapy response of breast cancer cells.
  • These findings suggest potential therapeutic strategies for modulating breast cancer chemotherapy by targeting growth factor signaling pathways.
  • Further research into growth factor interactions could lead to improved chemotherapeutic regimens for breast cancer.

More Related Videos

Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples07:03

Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples

Published on: October 2, 2020

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...